ABOS · Acumen Pharmaceuticals, Inc.
$2.13
-0.04 (-1.84%)
At close · Jul 24
Going-concern doubt
— flagged May 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company expects that its current balance of cash and cash equivalents and marketable securities may not be sufficient to fund its operations for at least 12 months from the date of issuance of these financial statements.”View the 10-Q filed May 12, 2026
Market Cap
$156.73M
Shares
72.23M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $1,863,567 |
| Jim Doherty | President and Chief Development Officer | $1,012,859 |
| Matthew Zuga | CFO | $948,789 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $4,780,687 |
| Jim Doherty | President and Chief Development Officer | $2,182,081 |
| Matthew Zuga | CFO | $1,689,514 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $3,930,011 |
| Matthew Zuga | CFO | $1,606,289 |
| Derek Meisner | Chief Legal Officer and Corporate Secretary | $1,476,637 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $2,662,052 |
| Derek Meisner | Chief Legal Officer and Corporate Secretary | $1,279,668 |
| Matthew Zuga | CFO | $1,188,786 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $1,477,836 |
| Matthew Zuga | CFO | $778,831 |
| Eric Siemers | Chief Medical Officer | $637,906 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Daniel O'Connell | CEO | $336,000 |
| Eric Siemers | Chief Medical Officer | $237,600 |
Key facts
CIK
1576885
CUSIP
00509G209
13F (30d)
10 filings
10 filers
Visit website
Investor relations